$ERAS News

Morgan Stanley Maintains Equal-Weight on Erasca, Raises Price Target to $21

Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?

Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers

Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results

Erasca Unveils Updated Cancer Candidate Progress, Maps Path Toward Pivotal Cancer Trials

B of A Securities Maintains Neutral on Erasca, Raises Price Target to $18

Erasca Announces Pricing of Upsized Public Offering of Common Stock

Erasca Announces Proposed Public Offering of $500 Million of Common Stock

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Erasca Plans To Commence $500M Common Stock Offering

Erasca Files Prospectus For Offering Mixed Shelf; Terms Undisclosed

Erasca Announces Updated Preliminary ERAS‑0015 Phase 1 Data And Clinical Plans, With Pivotal Lung And Pancreatic Cancer Trials Slated For 2027

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

Erasca (ERAS) Receives Encouraging Expert Feedback on ERAS-0015 Clinical Trials

Erasca (ERAS) Is Down 13.4% After IP Challenge to ERAS-0015 Trade Secrets and Patents

Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says

B of A Securities Upgrades Erasca to Neutral, Raises Price Target to $16

Erasca, Inc. (ERAS) Presents at Bank of America Global Healthcare Conference 2026 Transcript